Sally J Lawrence

Dr. Sally J Lawrence

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2017 in Frontiers in Pediatrics
Verified
Journal Article
Open access
SLSally J Lawrence
Sally J Lawrence
MSManish Sadarangani
Manish Sadarangani
KJKevan Jacobson
Kevan Jacobson
Immunosuppressive therapy is a known risk factor for opportunistic infections. We report the first case of severe Pneumocystis jirovecii infection requiring intensive care in a pediatric patient with inflammatory bowel disease (IBD). The literature was reviewed and there were 92 reported cases of pneumocystis pneumonia (PCP) in patients with IBD. Most sources were case reports and there was likely reporting bias towards patients receiving immunomodulators, anti-tumor necrosis factor (anti-TNF) therapy and those who died. Overall, 56% of patients were male and 58% had crohn’s disease (CD). The median age was 45 years (interquartile range 30-68, range 8-78) and 86% of patients were lymphopenic. The case-fatality rate was 23%. Corticosteroids were used as IBD treatment in 88% of patients who subsequently developed PCP, 42% received thiopurines, 44% used anti-TNF therapy and 15% received either ciclosporin or tacrolimus. Rates of mono, dual, triple and quadruple immunosuppression therapy were 35%, 35%, 29% and 2% respectively. This report highlights the importance of considering PCP in immunosuppressed lymphopenic pediatric IBD patients who present with unusual symptoms. Moreover, it should give gastroenterologists the impetus to limit immunosuppressive therapy to its minimal effective dose and consider options such as exclusive enteral nutrition (EEN) wherever possible. Although there is no place for global PCP prophylaxis in IBD given the low incidence, in an era when there is increasing use of biologic agents with combination immunosuppressive therapy, the risk-benefit profile of PCP chemoprophylaxis should be revisited in selected cohorts such as patients on triple immunosuppression with corticosteroids, thiopurines and a biological agent or calcineurin inhibitor, especially in lymphopenic individuals.

3 October 2023 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JDJennifer C. Debruyn
Jennifer C. Debruyn
HHHien Q. Huynh
Hien Q. Huynh
AGAnne M. Griffiths
Anne M. Griffiths
KJKevan Jacobson
Kevan Jacobson
DMDavid Mack
David Mack
TNThe Canadian Children Ibd Network
The Canadian Children Ibd Network
INTRODUCTION: This study compared real-world effectiveness between adalimumab (ADA) and infliximab (IFX) in children with Crohn's disease (CD). METHODS: Children enrolled into the prospective Canadian Children Inflammatory Bowel Disease Network National Inception Cohort between 2014 and 2020 who commenced ADA or IFX as first antitumor necrosis factor (anti-TNF) agent for luminal CD were included. Multivariate logistic regression modeled the propensity of commencing ADA; propensity score matching was used to match IFX-treated children to ADA-treated children. The primary outcome at 1 year was steroid-free clinical remission (SFCR). Secondary outcomes at 1 year were (i) combined SFCR and C-reactive protein remission, (ii) treatment intensification, and (iii) anti-TNF durability. Odds ratios (ORs) and hazard ratio adjusted for concomitant immunomodulator use with 95% confidence interval (CI) are reported. RESULTS: In the propensity score-matched cohort of 147 ADA-treated and 147 IFX-treated children, 92 (63%) ADA-treated and 87 (59%) IFX-treated children achieved SFCR at 1 year (adjusted OR 1.4, 95% CI 0.9–2.4); 75 of 140 (54%) ADA-treated and 85 of 144 (59%) IFX-treated children achieved combined SFCR and C-reactive protein remission (adjusted OR 1.0, 95% CI 0.6–1.6). ADA-treated children less frequently underwent treatment intensification (21 [14%]) compared with IFX-treated children (69 [47%]) (P < 0.0001). Discontinuation of anti-TNF occurred in 18 (12%) ADA-treated and 15 (10%) IFX-treated children (adjusted hazard ratio 1.2, 95% CI 0.6–2.2). DISCUSSION: Children with CD achieved favorable outcomes at 1 year with either ADA or IFX as first anti-TNF agents. Those receiving IFX did not have significantly superior outcomes compared with clinically similar children receiving ADA.

22 August 2022 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
SLSally J Lawrence
Sally J Lawrence
FFFarah Faytrouni
Farah Faytrouni
RHRachel E. MBChB Harris
Rachel E. MBChB Harris
MIMike Irvine
Mike Irvine
ECEstefania Carrion
Estefania Carrion
RRRichard K. Russell
Richard K. Russell

2 April 2025 in JMIR Pediatrics and Parenting
Verified
Journal Article
Open access
BABrooke Allemang
Brooke Allemang
AMAshleigh Miatello
Ashleigh Miatello
MBMira Browne
Mira Browne
MBMelanie Anne Barwick
Melanie Anne Barwick
PMPranshu Maini
Pranshu Maini
EBEric I Benchimol
Eric I Benchimol
Background: The transition from pediatric to adult health care marks a complex and pivotal process for adolescents and young adults with inflammatory bowel disease (IBD). This group requires support regarding disease self-management, skill development, and system navigation in preparation for transition. Evidence-based interventions are needed to promote optimal health and psychosocial outcomes for adolescents and young adults with IBD during this period. Objective: A qualitative study embedded within a randomized controlled trial was conducted to evaluate the perceived impact of a biopsychosocial transition intervention on the transition experiences of adolescents and young adults, their views on the intervention, and recommendations for future care. Methods: This patient-oriented research study used a qualitative descriptive design. Virtual semistructured interviews were held with 21 adolescents and young adults with IBD (16‐18 y) enrolled in the randomized controlled trial (intervention arm n=11 and control arm n=10). Interviews were audio-recorded, transcribed, and analyzed using an inductive approach to reflexive thematic analysis. Five members of a Youth Advisory Panel with lived experience of IBD collaborated throughout data analysis, interpretation, and the presentation of findings. Results: We constructed three themes through our analysis: (1) making meaning of transitions in care; (2) perceptions and impact of the biopsychosocial transition intervention; and (3) considerations for future transition care, including the importance of individualized support. Conclusions: Our findings illustrate the importance of relationships and the impact of a biopsychosocial intervention on adolescents’ and young adults’ confidence, knowledge, and self-management skills during transition. The results, which indicate the criticality of tailoring transition supports according to adolescents’ and young adults’ preferences and characteristics, will be used to refine the biopsychosocial intervention before it can be scaled and spread.

22 May 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
SLSally J Lawrence
Sally J Lawrence
MPMarina Viñeta Paramo
Marina Viñeta Paramo
FRFrederic Reicherz
Frederic Reicherz
JBJeffrey N. Bone
Jeffrey N. Bone
ZSZahra Jama Hussein Shire
Zahra Jama Hussein Shire
KJKevan Jacobson
Kevan Jacobson
Background/Objectives: Severe acute respiratory syndrome (SARS-CoV-2) has had a profound global impact and continues to represent a health challenge worldwide. The durability of SARS-CoV-2 vaccine responses in pediatric inflammatory bowel disease (PIBD) patients receiving biologic therapies is unknown. This study aimed to quantify SARS-CoV-2 antibody responses post vaccination in these immunosuppressed patients over 12 months. Methods: Prospective study comparing antibody responses against SARS-CoV-2 spike protein at 1, 3, 6, and 12 months in PIBD patients aged 5–18 years treated with anti-tumor necrosis factor alpha (anti-TNF) therapies with or without an immunomodulator (IM) versus vedolizumab. Results: Between 1 May 2021 and 1 May 2022, 194 participants on anti-TNF monotherapy (n = 78), anti-TNF with IM (n = 83), vedolizumab (n = 15), and steroids (n = 18) were recruited. Anti-SARS-CoV-2 spike levels increased after the first vaccine and were further boosted 1 month after the second dose. Linear mixed-effects modelling showed antibody waning over time (effect difference −2509 IgG AU/mL per week [95%CI: −4998–−20, p = 0.048]), counterbalanced by booster doses (effect difference 184,138 IgG AU/mL per additional vaccine dose [95%CI: 138,342–229,934, p < 0.001]). Receiving anti-TNF therapy contributed to reduced antibody responses compared to vedolizumab (anti-TNF monotherapy effect difference: −212,640 [95%CI: −336,928–−88,351] p = 0.001; anti-TNF with IM: −151,880 [95%CI: −277,309–−26,451] p = 0.018). Seroconversion and breakthrough infection rates were similar between groups, and all infections were mild, without hospitalizations. Conclusions: Although SARS-CoV-2 antibody responses were attenuated in PIBD patients receiving anti-TNF therapy compared with vedolizumab, this did not impact protection, as seroconversion and breakthrough infection rates were similar, with no hospitalizations. These data reinforce the importance of updating vaccines and, in particular, SARS-CoV-2 vaccines in immunosuppressed PIBD patients on advanced therapies.

9 December 2024 in Canadian IBD Today
Verified
Journal Article
Open access
PDF file
SKShreya B. Kishore
Shreya B. Kishore
SLSally J Lawrence
Sally J Lawrence
The therapeutic landscape for Crohn’s disease (CD) has been reshaped by improvements in disease management and medical therapy, leading to a decrease in the necessity for intestinal resection. However, surgical intervention still plays a crucial role in treating medically refractory disease or complications such as strictures or fistulae. Recent biologic-era population studies have shown that the rate of CD-related abdominal surgery over 10 years is up to 49.9% in adult-onset CD and 37.7% in pediatric onset CD.